Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

LSD1 pharmacological inhibition in SET-2 containing wild type and mutant LSD1 [ChIP-Seq]

ABSTRACT: LSD1 pharmacological inhibition in SET-2 containing wild type and mutant LSD1 [ChIP-Seq]

PROVIDER: PRJNA497302 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR8073140.fastq.gz	Fastqsanger.gz
	SRR8073140_1.fastq.gz	Fastqsanger.gz
	SRR8073140_2.fastq.gz	Fastqsanger.gz
	SRR8073150.fastq.gz	Fastqsanger.gz
	SRR8073150_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 60

Similar Datasets

LSD1 pharmacological inhibition in SET-2 containing wild type and mutant LSD1

Project description:LSD1 pharmacological inhibition in SET-2 containing wild type and mutant LSD1

| PRJNA497295 | ENA

LSD1 pharmacological inhibition in SET-2 containing wild type and mutant LSD1 [RNA-Seq]

Project description:LSD1 pharmacological inhibition in SET-2 containing wild type and mutant LSD1 [RNA-Seq]

| PRJNA497303 | ENA

LSD1 pharmacological inhibition in SET-2 containing wild type and mutant LSD1 [ChIP-Seq]

Project description:We characterized the changes in histone modifications as well as the localization of LSD1 and GFI1B for both wt SET-2 and drug-resistant SET-2 LSD1 (Leu659_Asn660insArg) treated with GSK-LSD1

2019-01-23 | GSE121424 | GEO

LSD1 pharmacological inhibition in SET-2 containing wild type and mutant LSD1 [RNA-Seq]

Project description:We characterized the effect of GSK-LSD1 treatment on gene expression for both wt SET-2 and drug-resistant SET-2 LSD1 (Leu659_Asn660insArg)

2019-01-23 | GSE121425 | GEO

Pharmacological LSD1 inhibition in MCC

Project description:Pharmacological LSD1 inhibition in MCC

| PRJNA621150 | ENA

LSD1 pharmacological inhibition in SET-2 containing wild type and mutant LSD1

Project description:This SuperSeries is composed of the SubSeries listed below.

2019-01-23 | GSE121426 | GEO

Transcriptomic maps of pharmacological LSD1 inhibition in MCC [SLAMseq]

Project description:Merkel cell carcinoma (MCC) is a highly aggressive, neuroendocrine skin cancer that lacks actionable mutations, which could be utilized for targeted therapies. Epigenetic regulators governing cell identity may represent unexplored therapeutic entry points. Here, we targeted epigenetic regulators in a pharmacological screen and discovered that the lysine-specific histone demethylase 1A (LSD1/KDM1A) is required for MCC growth in vitro and in vivo. We show that LSD1 inhibition in MCC disrupts the LSD1-CoREST complex leading to displacement and degradation of HMG20B (BRAF35), a poorly characterized complex member that is essential for MCC proliferation. Inhibition of LSD1 causes derepression of transcriptional master regulators of the neuronal lineage, activates a gene expression signature resembling normal Merkel cells, and induces cell cycle arrest and cell death. Our study unveils the importance of LSD1 for proliferation and maintaining cell identity in MCC. There is growing evidence that cancer cells exploit cellular plasticity and dedifferentiation programs to evade destruction by the immune system. The combination of LSD1 inhibitors with checkpoint inhibitors may thus represent a promising treatment strategy for MCC patients.

2020-09-04 | GSE147816 | GEO

Transcriptomic maps of pharmacological LSD1 inhibition in MCC [QUANTseq]

2020-09-04 | GSE147815 | GEO

Chromatin profiling upon pharmacological LSD1 inhibition in MCC [CUT&RUN]

2020-09-04 | GSE148103 | GEO

Transcriptomic maps of pharmacological LSD1 inhibition in MCC [QUANTseq]

Project description:Transcriptomic maps of pharmacological LSD1 inhibition in MCC [QUANTseq]

| PRJNA621229 | ENA